Guest columnist: FDA moving faster on psychedelics - State-Journal

The FDA is accelerating the regulatory review of psychedelic medicines, such as psilocybin, for serious mental health conditions following a presidential executive order. This shift aims to fast-track promising treatments for depression and other mental illnesses with clinical trials underway and potential DEA rescheduling to follow FDA approval.

This Wire brief sits within Fusion42's coverage of Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.